Compare Marathon Digital Holdings Inc (MARA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Sanofi SA — how do they compare? Marathon Digital Holdings Inc trades at $12.61 (market cap $4.45B), while Sanofi SA trades at $43.72 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 23.6× Marathon Digital Holdings Inc's market cap, and Sanofi SA pays a 5.5% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.
| MARA | SNY | |
|---|---|---|
Market Cap | $4.45B | $104.83B |
Sector | Technology | Health |
52-Week High | $22.84 | $52.34 |
52-Week Low | $6.73 | $41.33 |
Enterprise Value | $6.40B | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Digital Holdings (MARA) trades at $11.67, up 9.17% today, amid a strategic pivot from Bitcoin mining to AI infrastructure. Despite recent earnings misses and negative profitability metrics, the stock shows technical support near $10-11 levels. The company's acquisition of a 1,200-acre Texas site with 2 GW power capacity represents a significant expansion opportunity, though cash flow remains negative from operations.
MARA presents a high-risk opportunity with Wall Street analysts maintaining a 50% buy rating and $16.90 consensus target. The AI pivot could drive long-term growth, but investors face substantial execution risks amid persistent losses and negative cash flow. Near-term performance depends on successful business transformation and improved profitability.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
